IQV
IQVIA Holdings Inc.
171.11
1 x 171.70
1 x 171.80
bid
ask
+
0.43
0.25%
03:46 PM
timesize
Ytd -24.09%
1y 21.85%
168.68
day range
173.32
137.00
52 week range
244.29
Open 170.07 Prev Close 170.68 Low 168.68 High 173.32 Mkt Cap 28.49B
Vol 1.03M Avg Vol 1.84M EPS 8.06 P/E 21.18 Forward P/E 12.15
Beta 1.18 Short Ratio 3.34 Inst. Own 104.10% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 07-21 50-d Avg 169.64 200-d Avg 196.50 1yr Est 228.60
Earning
Date For Estimate Reported Surprise surprise %
2026-05-05 2026-03 2.83 2.9 0.07 2.47%
2026-02-05 2025-12 3.4 3.42 0.02 0.59%
2025-10-28 2025-09 2.96 3 0.04 1.35%
2025-07-22 2025-06 2.76 2.81 0.05 1.81%
2025-05-06 2025-03 2.63 2.7 0.07 2.66%
2025-02-06 2024-12 3.1 3.12 0.02 0.65%
Upgrade / Downgrade
Date Firm Action From To
2026-04-08 Evercore ISI Group Upgrade Outperform Outperform
2026-03-09 TD Cowen Upgrade Hold Buy
2026-03-06 Barclays Upgrade Equal-Weight Overweight
2026-03-03 RBC Capital Upgrade Outperform
2026-02-19 Truist Securities Upgrade Buy Buy
2026-02-06 JP Morgan Upgrade Overweight Overweight
Profile
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Insider Holder
Date Name Relation Quantity Description
2026-02-05 BOUSBIB ARI B Chief Executive Officer 1.38M Stock Award(Grant)
2026-02-05 BRUEHLMAN RONALD E Chief Financial Officer 56.00K Stock Award(Grant)
2026-04-22 BURT CAROL J Director 0.00 Stock Award(Grant)
2026-02-05 CHEROFSKY KERIANN Officer 3.55K Stock Award(Grant)
2026-04-22 DANHAKL JOHN G Director 0.00 Stock Award(Grant)
2026-04-22 GOGGINS COLLEEN A Director 14.45K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2026-03-30 Blackrock Inc. 15.03M 2.57B 9.00%
2025-12-30 Harris Associates L.P. 11.32M 1.93B 6.78%
2026-03-30 Vanguard Capital Management LLC 11.03M 1.88B 6.61%
2026-03-30 Vanguard Portfolio Management LLC 7.58M 1.29B 4.54%
2025-12-30 State Street Corporation 7.45M 1.27B 4.46%
2026-03-30 JPMORGAN CHASE & CO 5.41M 923.42M 3.24%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 5.09M 869.00M 3.05%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 4.29M 733.29M 2.57%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund 3.52M 601.31M 2.11%
2025-12-30 HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Fund 2.71M 462.64M 1.62%
2026-03-30 iShares Trust-iShares Core S&P 500 ETF 2.18M 372.29M 1.31%
2026-03-30 Fidelity Concord Street Trust-Fidelity 500 Index Fund 2.17M 369.85M 1.30%